ArticleEuropean journal of drug metabolism and pharmacokinetics2026
Population Pharmacokinetics of Amikacin in Non-Neonatal Pediatric Patients: A Scoping Review.
Article in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAmikacin remains an important agent in managing severe Gram-negative infections in children. However, its clinical use is limited by a narrow therapeutic index and pronounced pharmacokinetic (PK) variability. Population pharmacokinetic (PopPK) modeling offers a framework for individualized dosing, yet evidence in non-neonatal pediatric populations remains fragmented.
methodsA scoping review was conducted across PubMed, Scopus, and Web of Science (last updated July 2025) to identify PopPK studies evaluating intravenous amikacin in children aged 1 month to 18 years. Eligible studies applied nonlinear mixed effects modeling and reported structural models, PK parameters, and covariate analyses. Methodological quality was assessed using a 38-item checklist adapted from established guidelines.
resultsOf 783 records screened, 8 studies met the inclusion criteria. Most were retrospective, with sparse PK sampling from routine therapeutic drug monitoring (TDM) data. Body weight was the most consistently identified predictor, while renal function, age, and disease state were retained in selected models. Burn, cystic fibrosis, and oncology populations demonstrated consistently higher clearance and/or volume of distribution, often requiring higher doses for pharmacodynamic target attainment. None of the included studies performed external validation, limiting generalizability.
conclusionsAmikacin PK in children is highly variable and disease-specific. Conventional weight-based dosing is frequently insufficient. Integration of model-informed precision dosing (MIPD) with TDM is essential to optimize amikacin therapy in pediatric practice, particularly in high-risk subpopulations.
Indexed as
Identifiers
42360659What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.